Cover Image
市场调查报告书

EpiCast Report:痛风的流行病学预测

EpiCast Report: Gout - Epidemiology Forecast to 2023

出版商 GlobalData 商品编码 300492
出版日期 内容信息 英文 55 Pages
订单完成后即时交付
价格
Back to Top
EpiCast Report:痛风的流行病学预测 EpiCast Report: Gout - Epidemiology Forecast to 2023
出版日期: 2014年04月24日 内容信息: 英文 55 Pages
简介

痛风是发炎性关节炎的一种,是由于关节内部的尿酸结晶化所引发的疾病。此外也与高尿酸血症有关。全球主要6个国家的痛风发病人数,预测将由2013年的1,374,065人,增加到2023年的1,649,065人(年平均增加率为2.00%)。此外接受诊断的患病者人数推计将由2013年的17,625,944人,增加到2023年的17,625,944人(年平均成长率为2.82%)。

本报告提供全球主要6个国家(美国·法国·德国·义大利·西班牙·英国)的痛风发病情形和今后预测相关分析,提供疾病的特徵(风险要素和主要的并发症等等)全球各国的趋势,目前患病者的发病情形,今后10年的发病·患病数量预测值等调查评估,并将其结果为您概述为以下内容。

第1章 目录

第2章 简介

  • 概要
  • 近日出版的相关调查

第3章 流行病学

  • 疾病的背景
  • 风险要素和并发症
  • 全世界的趋势
    • 美国
    • 欧洲主要5个国家
  • 预测手法
    • 利用之信息来源
    • 未利用之信息来源
    • 预测的前提条件与手法
  • 痛风的流行病学预测(今后11年份)
    • 接受诊断的发病人数
    • 接受诊断的患病人数
  • 议论
    • 流行病学的预测相关结论
    • 分析的限制
    • 分析的优势

第4章 附录

图表一览

目录
Product Code: GDHCER058

Gout is a type of inflammatory arthritis. The disease is triggered by the crystallization of uric acid within the joints and is associated with hyperuricemia, a condition in which the body either overproduces or under excretes uric acid. Attacks of gout are episodic in nature and although months may pass before the next attack occurs, the pain experienced during an attack can be debilitating. Men are at a higher risk for developing gout and the risk also increases with age, with a mean age at diagnosis for gout in both men and women of 61 years.

GlobalData epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%.

This forecast is supported by age- and sex-specific data obtained from country-specific estimates from peer reviewed journal articles, in which the study populations were representative of the general population in the respective markets. GlobalData epidemiologists used historical diagnosed incidence and diagnosed prevalence data which were available for Italy and the UK, along with linear regression methods to forecast the age- and sex-specific diagnosed incidence and diagnosed prevalence for Italy and the UK through 2023. The forecast provides the age- and sex-specific diagnosed incident cases and diagnosed prevalent cases of gout in each of the 6MM, with clinically relevant segmentations, which facilitate an in depth understanding of the emerging temporal trends, and informs strategies to improve the management of the disease. Additionally, GlobalData epidemiologists used the same methodology across the 6MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of gout across these markets.

Scope

  • The Gout EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at =85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.
  • The gout epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global gout market.
  • Quantify patient populations in the global gout market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gout therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Gout (2013-2023)
    • 3.5.1. Diagnosed Incidence
    • 3.5.2. Diagnosed Prevalence
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Gout
  • Table 2: Summary of Reported Incidence and Prevalence of Gout in the 6MM*
  • Table 3: American College of Rheumatology Criteria for the Clinical Diagnosis of Gout
  • Table 4: Sources of Gout Incidence Data in 6MM
  • Table 5: Sources of Gout Prevalence Data in 6MM
  • Table 6: Sources of Gout Flare and Tophaceous Gout Data in 6MM
  • Table 7: 6MM, Sources Not Used in the Epidemiological Analysis of Gout
  • Table 8: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 9: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 10: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N (Row %), 2013
  • Table 11: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 12: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 13: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N (Row %), 2013

List of Figures

  • Figure 1: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Diagnosed Incidence of Gout (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 6: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N, 2013
  • Figure 7: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 8: 6MM, Age-Standardized Diagnosed Prevalence (%) of Gout, Ages ≥20 Years, by Sex, 2013
  • Figure 9: 6MM, Number of Gout Flares in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
  • Figure 10: 6MM, Tophaceous Gout Cases in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
Back to Top